<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02334982</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-137_101</org_study_id>
    <secondary_id>U1111-1164-7376</secondary_id>
    <nct_id>NCT02334982</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-137 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and tolerability profile of TAK-137
      when administered as a single dose of tablets at escalating dose levels in healthy
      participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-137. TAK-137 is being tested to find a safe
      and well-tolerated dose. This study looked at safety (lab results and side effects) and
      pharmacokinetic properties (drug absorption, distribution, metabolism, and excretion) in
      people who took TAK-137. This study was designed as a single ascending 6 Cohort dose study
      with planned doses of 2, 5, 15, 50, and 100 mg and Cohort 6 dose to be determined if the
      maximum tolerated dose (MTD) was not reached. Anticipated enrollment was 48.

      This study enrolled 47 participants and consisted of 6 Cohorts. Participants in Cohorts 1, 2,
      3, 5 and 6 were randomized to receive a single dose of TAK-137 or placebo after a 10-hour
      fast. Participants in Cohort 4 were randomized to receive a single dose of TAK-137 or placebo
      under fasted conditions, followed by a single dose of TAK-137 or placebo under fed conditions
      14 days later. Participants in cohort 4 will receive the same dose in both fasted and fed
      conditions. The starting dose was 2 mg followed by administrations of 5, 10, 0.5 and 20 mg.

      This single-center trial was conducted in the United States. For Cohorts 1, 2, 3, 5, and 6
      the overall time to participate in this study was up to 42 days. Participants made 4 visits
      to the clinic including one 5-day period of confinement to the clinic, and were contacted by
      telephone 14 days after last dose of study drug for a follow-up assessment.

      For Cohort 4 the overall time to participate in this study was up to 56 days. Participants
      made 7 visits to the clinic including two 5-day periods of confinement to the clinic, and
      were contacted by telephone 14 days after last dose of study drug for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event</measure>
    <time_frame>Day 1 to 14 days after the last dose of study medication(Up to 30 days)</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Abnormal Safety Laboratory Findings</measure>
    <time_frame>Day 1 to 14 days after the last dose of study medication (Up to 30 Days)</time_frame>
    <description>The percentage of participants with any markedly abnormal standard safety laboratory values was collected throughout study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Markedly Abnormal Vital Sign Measurements</measure>
    <time_frame>Day 1 to 14 days after the last dose of study medication</time_frame>
    <description>The percentage of participants with any markedly abnormal standard vital sign measurements was collected throughout study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-137</measure>
    <time_frame>Day 1</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-137</measure>
    <time_frame>Day 1</time_frame>
    <description>Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-137</measure>
    <time_frame>Day 1</time_frame>
    <description>(AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-137</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (T1/2) for TAK-137_101</measure>
    <time_frame>Day 1</time_frame>
    <description>Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) for TAK-137_101</measure>
    <time_frame>Day 1</time_frame>
    <description>CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-inf), expressed in liters per hour (L/hr).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for TAK-137_101</measure>
    <time_frame>Day 1</time_frame>
    <description>Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Drug (TAK-137) Excreted in Urine From Time 0 to Time t (Ae[0-t])</measure>
    <time_frame>Day 1</time_frame>
    <description>Total amount of drug excreted in urine from time 0 to time t, calculated as Sum (Cu*Vu), where Cu is the concentration of drug excreted in urine and Vu is the volume of urine excreted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of TAK-137 Excreted in Urine (Fe)</measure>
    <time_frame>Day 1</time_frame>
    <description>Fraction of drug excreted in urine, calculated as Fe=(Ae[0-t]/dose)×100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLr) for TAK-137</measure>
    <time_frame>Day 1</time_frame>
    <description>CLr is a measure of apparent clearance of the drug from the urine, calculated as CLr=Ae(0-t)/AUC(0-96).</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Dose Finding Study</condition>
  <arm_group>
    <arm_group_label>Cohort 1: TAK-137 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-137 2 mg, tablets, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: TAK-137 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-137 5 mg, tablets, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: TAK-137 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: TAK-137 5 mg Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: TAK-137 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-137 0.5 mg, tablets, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: TAK-137 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-137 20 mg, tablets, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohorts 1-6: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-137 placebo-matching tablets, orally, once on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-137</intervention_name>
    <description>TAK-137 tablets</description>
    <arm_group_label>Cohort 1: TAK-137 2 mg</arm_group_label>
    <arm_group_label>Cohort 2: TAK-137 5 mg</arm_group_label>
    <arm_group_label>Cohort 3: TAK-137 10 mg</arm_group_label>
    <arm_group_label>Cohort 4: TAK-137 5 mg Food Effect</arm_group_label>
    <arm_group_label>Cohort 5: TAK-137 0.5 mg</arm_group_label>
    <arm_group_label>Cohort 6: TAK-137 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TAK-137 placebo-matching tablets</description>
    <arm_group_label>Cohorts 1-6: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a healthy male or non-pregnant, non-lactating female adult who is 18 to 55 years of
             age inclusive at the time of informed consent and first study medication dose.

          2. Weighs at least 45 kg and has a body mass index (BMI) between 18 and 30.0 kg/m^2,
             inclusive at Screening.

          3. Is able to comply with the protocol and is willing to sign the informed consent prior
             to undergoing any study-related procedures.

        Exclusion Criteria:

          1. Has a known hypersensitivity to any component of the formulation of TAK-137.

          2. Has a medical condition such as mental retardation that can cause cognitive
             impairment.

          3. Has a risk of suicide according to the Investigator's clinical judgment (eg, per
             Columbia-Suicide Severity Rating Scale [C-SSRS] or has made a suicide attempt in the
             previous 6 months).

          4. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic
             disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy,
             asthma hypoxemia, hypertension, seizures, or allergic skin rash.

          5. There is any finding in the participant's medical history, physical examination, or
             safety laboratory tests (including safety electroencephalogram [EEG]) giving
             reasonable suspicion of a disease that would contraindicate taking TAK-137, or a
             similar drug in the same class, or that might interfere with the conduct of the study.
             This includes, but is not limited to, peptic ulcer disease, seizure disorders, and
             cardiac arrhythmias.

          6. Has taken any excluded medication, supplements, or food products listed in the
             Excluded Medications and Dietary Products table.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2015</study_first_posted>
  <results_first_submitted>January 29, 2015</results_first_submitted>
  <results_first_submitted_qc>January 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2015</results_first_posted>
  <last_update_submitted>January 29, 2015</last_update_submitted>
  <last_update_submitted_qc>January 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United States from 21 June 2013 to 30 January 2014.</recruitment_details>
      <pre_assignment_details>Healthy Volunteers were enrolled in a 6 Cohort randomized, dose escalating study at doses of 0.5, 2,5, 10 and 20 mg TAK-137 tablets or placebo single dose once in Cohorts 5,1,2,3 and 6 fasting respectively. Cohort 4 received 5 mg tablets or placebo single dose fasting then 5 mg or placebo fed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: TAK-137 2 mg</title>
          <description>TAK-137 2 mg, tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: TAK-137 5 mg</title>
          <description>TAK-137 5 mg, tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3: TAK-137 10 mg</title>
          <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4: TAK-137 5 mg Food Effect</title>
          <description>TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5: TAK-137 0.5 mg</title>
          <description>TAK-137 0.5 mg, tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 6: TAK-137 20 mg</title>
          <description>TAK-137 20 mg, tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Cohorts 1-6: Placebo</title>
          <description>TAK-137 placebo-matching tablets, orally, once on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: TAK-137 2 mg</title>
          <description>TAK-137 2 mg, tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: TAK-137 5 mg</title>
          <description>TAK-137 5 mg, tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3: TAK-137 10 mg</title>
          <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4: TAK-137 5 mg Food Effect</title>
          <description>TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5: TAK-137 0.5 mg</title>
          <description>TAK-137 0.5 mg, tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 6: TAK-137 20 mg</title>
          <description>TAK-137 20 mg, tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Cohorts 1-6: Placebo</title>
          <description>TAK-137 placebo-matching tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.8" spread="9.00"/>
                    <measurement group_id="B2" value="34.0" spread="8.66"/>
                    <measurement group_id="B3" value="40.5" spread="8.22"/>
                    <measurement group_id="B4" value="36.5" spread="9.27"/>
                    <measurement group_id="B5" value="24.7" spread="3.88"/>
                    <measurement group_id="B6" value="38.5" spread="10.63"/>
                    <measurement group_id="B7" value="31.5" spread="6.87"/>
                    <measurement group_id="B8" value="34.9" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.3" spread="8.19"/>
                    <measurement group_id="B2" value="173.2" spread="13.22"/>
                    <measurement group_id="B3" value="178.0" spread="6.63"/>
                    <measurement group_id="B4" value="172.3" spread="8.62"/>
                    <measurement group_id="B5" value="171.5" spread="6.44"/>
                    <measurement group_id="B6" value="164.7" spread="11.74"/>
                    <measurement group_id="B7" value="166.2" spread="9.44"/>
                    <measurement group_id="B8" value="171.6" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.97" spread="15.299"/>
                    <measurement group_id="B2" value="79.86" spread="14.870"/>
                    <measurement group_id="B3" value="81.88" spread="15.381"/>
                    <measurement group_id="B4" value="74.40" spread="18.840"/>
                    <measurement group_id="B5" value="75.05" spread="12.228"/>
                    <measurement group_id="B6" value="64.18" spread="14.297"/>
                    <measurement group_id="B7" value="73.23" spread="9.378"/>
                    <measurement group_id="B8" value="74.23" spread="15.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.22" spread="3.276"/>
                    <measurement group_id="B2" value="26.48" spread="2.138"/>
                    <measurement group_id="B3" value="25.68" spread="3.323"/>
                    <measurement group_id="B4" value="24.68" spread="4.260"/>
                    <measurement group_id="B5" value="25.38" spread="2.905"/>
                    <measurement group_id="B6" value="23.38" spread="2.315"/>
                    <measurement group_id="B7" value="26.51" spread="2.658"/>
                    <measurement group_id="B8" value="24.93" spread="3.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Consumption</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.</description>
        <time_frame>Day 1 to 14 days after the last dose of study medication(Up to 30 days)</time_frame>
        <population>Safety population included all participants who received at least one dose of study medication. 8 of the 47 enrolled participants participated in Cohort 4 fed.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>TAK-137 Placebo</title>
            <description>TAK-137 placebo-matching tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
          <group group_id="O8">
            <title>Placebo (Fed)</title>
            <description>TAK-137 placebo-matching tablets, orally, fed, once on Day 1of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.</description>
          <population>Safety population included all participants who received at least one dose of study medication. 8 of the 47 enrolled participants participated in Cohort 4 fed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Abnormal Safety Laboratory Findings</title>
        <description>The percentage of participants with any markedly abnormal standard safety laboratory values was collected throughout study.</description>
        <time_frame>Day 1 to 14 days after the last dose of study medication (Up to 30 Days)</time_frame>
        <population>Participants from the Safety population, all participants who received at least one dose of study medication, with data available for analysis. 8 of the 47 enrolled participants participated in Cohort 4 fed.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Fasting</title>
            <description>TAK-137 placebo-matching tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
          <group group_id="O8">
            <title>Placebo (Fed)</title>
            <description>TAK-137 placebo-matching tablets, orally, fed, once on Day 1of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Abnormal Safety Laboratory Findings</title>
          <description>The percentage of participants with any markedly abnormal standard safety laboratory values was collected throughout study.</description>
          <population>Participants from the Safety population, all participants who received at least one dose of study medication, with data available for analysis. 8 of the 47 enrolled participants participated in Cohort 4 fed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Markedly Abnormal Vital Sign Measurements</title>
        <description>The percentage of participants with any markedly abnormal standard vital sign measurements was collected throughout study.</description>
        <time_frame>Day 1 to 14 days after the last dose of study medication</time_frame>
        <population>Participants from the Safety population, all participants who received at least one dose of study medication, with data available for analysis. 8 of the 47 enrolled participants participated in Cohort 4 fed.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>TAK-137 Placebo</title>
            <description>TAK-137 placebo-matching tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
          <group group_id="O8">
            <title>Placebo (Fed)</title>
            <description>TAK-137 placebo-matching tablets, orally, fed, once on Day 1of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Markedly Abnormal Vital Sign Measurements</title>
          <description>The percentage of participants with any markedly abnormal standard vital sign measurements was collected throughout study.</description>
          <population>Participants from the Safety population, all participants who received at least one dose of study medication, with data available for analysis. 8 of the 47 enrolled participants participated in Cohort 4 fed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse (5 min after supine) &lt;50 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="8.3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse (5 min after supine) &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse (1 min after standing) &lt;50 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse (1 min after standing) &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="8.3"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse (3 min after standing) &lt;50 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse (3 min after standing) &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="8.3"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP (5 min after supine) &lt;85 mmHG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP (5 min after supine) &gt;180 mmHG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP (1 min after standing) &lt;85 mmHG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP (1 min after standing) &gt;180 mmHG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP (3 min after standing) &lt;85 mmHG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="9.1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP (3 min after standing) &gt;180 mmHG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (5 min after supine) &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (5 min after supine) &gt;110 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (1 min after standing) &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (1 min after standing) &gt;110 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (3 min after standing) &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (3 min after standing) &gt;110 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-137</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Day 1</time_frame>
        <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-137</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="8.64"/>
                    <measurement group_id="O2" value="68.90" spread="7.40"/>
                    <measurement group_id="O3" value="121.1" spread="28.44"/>
                    <measurement group_id="O4" value="61.1" spread="16.11"/>
                    <measurement group_id="O5" value="9.0" spread="0.76"/>
                    <measurement group_id="O6" value="206.1" spread="80.72"/>
                    <measurement group_id="O7" value="85.9" spread="28.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-137</title>
        <description>Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.</description>
        <time_frame>Day 1</time_frame>
        <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-137</title>
          <description>Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.</description>
          <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O3" value="3.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="2.50" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O6" value="2.50" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O7" value="5.50" lower_limit="2.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-137</title>
        <description>(AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
        <time_frame>Day 1</time_frame>
        <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-137</title>
          <description>(AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
          <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405" spread="121.6"/>
                    <measurement group_id="O2" value="1668" spread="787.6"/>
                    <measurement group_id="O3" value="3012" spread="2204.1"/>
                    <measurement group_id="O4" value="1191" spread="767.9"/>
                    <measurement group_id="O5" value="94" spread="41.9"/>
                    <measurement group_id="O6" value="5346" spread="3292.4"/>
                    <measurement group_id="O7" value="1470" spread="434.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-137</title>
        <description>AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
        <time_frame>Day 1</time_frame>
        <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-137</title>
          <description>AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
          <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408" spread="121.64"/>
                    <measurement group_id="O2" value="1696" spread="803.9"/>
                    <measurement group_id="O3" value="3135" spread="2380.8"/>
                    <measurement group_id="O4" value="1198" spread="766.64"/>
                    <measurement group_id="O5" value="97" spread="43.24"/>
                    <measurement group_id="O6" value="5353" spread="3295.2"/>
                    <measurement group_id="O7" value="1474" spread="436.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (T1/2) for TAK-137_101</title>
        <description>Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
        <time_frame>Day 1</time_frame>
        <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T1/2) for TAK-137_101</title>
          <description>Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
          <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.65" spread="2.462"/>
                    <measurement group_id="O2" value="12.66" spread="2.491"/>
                    <measurement group_id="O3" value="13.60" spread="7.105"/>
                    <measurement group_id="O4" value="15.77" spread="10.553"/>
                    <measurement group_id="O5" value="8.54" spread="4.487"/>
                    <measurement group_id="O6" value="13.09" spread="5.276"/>
                    <measurement group_id="O7" value="10.52" spread="3.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F) for TAK-137_101</title>
        <description>CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-inf), expressed in liters per hour (L/hr).</description>
        <time_frame>Day 1</time_frame>
        <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) for TAK-137_101</title>
          <description>CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-inf), expressed in liters per hour (L/hr).</description>
          <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
          <units>liters/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="1.304"/>
                    <measurement group_id="O2" value="3.66" spread="1.912"/>
                    <measurement group_id="O3" value="5.23" spread="3.877"/>
                    <measurement group_id="O4" value="5.91" spread="3.372"/>
                    <measurement group_id="O5" value="6.26" spread="3.062"/>
                    <measurement group_id="O6" value="7.19" spread="6.976"/>
                    <measurement group_id="O7" value="3.63" spread="0.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) for TAK-137_101</title>
        <description>Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by λz.</description>
        <time_frame>Day 1</time_frame>
        <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) for TAK-137_101</title>
          <description>Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by λz.</description>
          <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.57" spread="15.521"/>
                    <measurement group_id="O2" value="62.26" spread="23.596"/>
                    <measurement group_id="O3" value="81.23" spread="47.499"/>
                    <measurement group_id="O4" value="134.49" spread="150.393"/>
                    <measurement group_id="O5" value="62.85" spread="14.652"/>
                    <measurement group_id="O6" value="110.48" spread="86.222"/>
                    <measurement group_id="O7" value="52.97" spread="17.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Drug (TAK-137) Excreted in Urine From Time 0 to Time t (Ae[0-t])</title>
        <description>Total amount of drug excreted in urine from time 0 to time t, calculated as Sum (Cu*Vu), where Cu is the concentration of drug excreted in urine and Vu is the volume of urine excreted.</description>
        <time_frame>Day 1</time_frame>
        <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Drug (TAK-137) Excreted in Urine From Time 0 to Time t (Ae[0-t])</title>
          <description>Total amount of drug excreted in urine from time 0 to time t, calculated as Sum (Cu*Vu), where Cu is the concentration of drug excreted in urine and Vu is the volume of urine excreted.</description>
          <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0039" spread="0.00161"/>
                    <measurement group_id="O2" value="0.0164" spread="0.01492"/>
                    <measurement group_id="O3" value="0.0470" spread="0.04281"/>
                    <measurement group_id="O4" value="0.0192" spread="0.01465"/>
                    <measurement group_id="O5" value="0.0002" spread="0.00034"/>
                    <measurement group_id="O6" value="0.0585" spread="0.04417"/>
                    <measurement group_id="O7" value="0.0217" spread="0.01335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of TAK-137 Excreted in Urine (Fe)</title>
        <description>Fraction of drug excreted in urine, calculated as Fe=(Ae[0-t]/dose)×100.</description>
        <time_frame>Day 1</time_frame>
        <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of TAK-137 Excreted in Urine (Fe)</title>
          <description>Fraction of drug excreted in urine, calculated as Fe=(Ae[0-t]/dose)×100.</description>
          <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
          <units>percent excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.080"/>
                    <measurement group_id="O2" value="0.33" spread="0.298"/>
                    <measurement group_id="O3" value="0.47" spread="0.428"/>
                    <measurement group_id="O4" value="0.38" spread="0.293"/>
                    <measurement group_id="O5" value="0.04" spread="0.068"/>
                    <measurement group_id="O6" value="0.29" spread="0.221"/>
                    <measurement group_id="O7" value="0.43" spread="0.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (CLr) for TAK-137</title>
        <description>CLr is a measure of apparent clearance of the drug from the urine, calculated as CLr=Ae(0-t)/AUC(0-96).</description>
        <time_frame>Day 1</time_frame>
        <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-137 2 mg</title>
            <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-137 10 mg</title>
            <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-137 5 mg (Fasting)</title>
            <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-137 0.5 mg</title>
            <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: TAK-137 20 mg</title>
            <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: TAK-137 5 mg (Fed)</title>
            <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) for TAK-137</title>
          <description>CLr is a measure of apparent clearance of the drug from the urine, calculated as CLr=Ae(0-t)/AUC(0-96).</description>
          <population>Participants from the Pharmacokinetic (PK) set, all participants who receive study drug and have at least one measureable concentration, with data available for analysis of this outcome measure.</population>
          <units>liters/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0093" spread="0.00268"/>
                    <measurement group_id="O2" value="0.0094" spread="0.00577"/>
                    <measurement group_id="O3" value="0.0138" spread="0.00477"/>
                    <measurement group_id="O4" value="0.0164" spread="0.00626"/>
                    <measurement group_id="O5" value="0.0031" spread="0.00500"/>
                    <measurement group_id="O6" value="0.0117" spread="0.00453"/>
                    <measurement group_id="O7" value="0.0150" spread="0.00804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to 14 days after the last dose of study medication (Up to 30 days).</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAK-137 0.5 mg</title>
          <description>TAK-137 0.5 mg, tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>TAK-137 2 mg</title>
          <description>TAK-137 2 mg, tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>TAK-137 5 mg (Fasting)</title>
          <description>TAK-137 5 mg, tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>TAK-137 10 mg</title>
          <description>TAK-137 10 mg, tablets, orally, once on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>TAK-137 20 mg</title>
          <description>TAK-137 20 mg, tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Placebo Fasting</title>
          <description>TAK-137 placebo-matching tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>TAK-137 5 mg (Fed)</title>
          <description>TAK-137 5 mg, tablets, orally, fed, once, on Day 1 of Period 2.</description>
        </group>
        <group group_id="E8">
          <title>Placebo (Fed)</title>
          <description>TAK-137 placebo-matching tablets, orally, fed, once on Day 1of Period 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Orthostatic heart rate response increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

